Keros Therapeutics, Inc.KROSEarnings & Financial Report
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel targeted therapies for hematological disorders, musculoskeletal diseases and anemia, serving underserved patient groups with unmet medical needs from its core U.S. base.
KROS Q4 FY2025 Key Financial Metrics
Revenue
$385.0K
Gross Profit
N/A
Operating Profit
N/A
Net Profit
N/A
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
YoY Growth
-87.3%
Keros Therapeutics, Inc. Q4 FY2025 Financial Summary
Keros Therapeutics, Inc. reported revenue of $385.0K (down 87.3% YoY) for Q4 FY2025, with a net profit of N/A (up 49.0% YoY) (N/A margin).
Key Financial Metrics
| Total Revenue | $385.0K |
|---|---|
| Net Profit | N/A |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q4 FY2025 |
Keros Therapeutics, Inc. Annual Revenue by Year
Keros Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $244.1M).
Keros Therapeutics, Inc. Quarterly Revenue & Net Profit History
Keros Therapeutics, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $385.0K | -87.3% | N/A | N/A |
| Q3 FY2025 | $14.3M | +3575.8% | $-7.3M | -51.0% |
| Q2 FY2025 | $18.2M | +49002.7% | $-30.7M | -169.0% |
| Q1 FY2025 | $211.2M | +254413.3% | $148.5M | 70.3% |
| Q3 FY2024 | $388.0K | +4750.0% | $-53.0M | -13648.5% |
| Q2 FY2024 | $37.0K | — | $-45.3M | -122316.2% |
| Q1 FY2024 | $83.0K | — | $-43.1M | -51944.6% |
| Q3 FY2023 | $8.0K | — | $-39.4M | -493000.0% |
Income Statement
| Q3 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $8000 | $83000 | $37000 | $388000 | $211.2M | $18.2M | $14.3M | $385000 |
| YoY Growth | N/A | N/A | N/A | 4750.0% | 254413.3% | 49002.7% | 3575.8% | -87.3% |
Balance Sheet
| Q3 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $326.2M | $485.8M | $455.0M | $579.3M | $784.6M | $757.2M | $742.8M | $338.0M |
| Liabilities | $30.4M | $31.9M | $34.1M | $46.4M | $55.7M | $50.4M | $39.2M | $34.9M |
| Equity | $295.8M | $453.9M | $420.9M | $532.8M | $728.9M | $706.7M | $703.6M | $303.1M |
Cash Flow
| Q3 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-34.0M | $-44.6M | $-39.8M | $-30.5M | $161.2M | $-29.6M | $3.2M | $107.5M |